Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
TINEA
MCID: DRM011
MIFTS: 45

Dermatophytosis (TINEA)

Categories: Infectious diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dermatophytosis

About this section

MalaCards integrated aliases for Dermatophytosis:

Name: Dermatophytosis 12 76 15 73
Tinea 73

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:8913
ICD10 33 B35 B35.9
ICD9CM 35 110 110.9
NCIt 50 C26745
SNOMED-CT 68 47382004
Sources

Summaries for Dermatophytosis

About this section
Disease Ontology : 12 A cutaneous mycosis that results in fungal infection located in scalp, located in glabrous skin, or located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source.

MalaCards based summary : Dermatophytosis, also known as tinea, is related to tinea corporis and tinea cruris, and has symptoms including fever, pruritus and exanthema. An important gene associated with Dermatophytosis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways is GPCRs, Class B Secretin-like. The drugs Omeprazole and Ciclopirox have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

CDC : 3 Ringworm poster: Protect Yourself From Itchy Rashes [PDF – 1 page]

Wikipedia : 76 Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a... more...

Sources

Related Diseases for Dermatophytosis

About this section

Diseases related to Dermatophytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 tinea corporis 33.3 DEFB4A SQLE
2 tinea cruris 33.2 DEFB4A SQLE
3 tinea capitis 32.8 CARD9 FLNC KATNAL2
4 candidiasis 30.3 CARD9 DEFB4A
5 deep dermatophytosis 12.5
6 tinea pedis 11.9
7 tinea unguium 11.8
8 tinea manuum 11.8
9 tinea profunda 11.7
10 tinea barbae 11.6
11 dermatomycosis 11.3
12 candidiasis, familial, 2 11.0
13 superficial mycosis 11.0
14 tinea imbricata 10.5
15 tinea favosa 10.5
16 dermatitis 10.2
17 aseptic meningitis 10.1 CSF1 LTF
18 oral candidiasis 10.1 DEFB4A LTF
19 chronic mucocutaneous candidiasis 10.1
20 lymphoma 10.0
21 urticaria 10.0
22 psoriasis 10.0
23 pemphigus 10.0
24 kerion celsi 10.0
25 opportunistic mycosis 10.0 CARD9 FLNC
26 gingivitis 9.9 DEFB4A LTF
27 adult t-cell leukemia 9.9
28 leukemia 9.9
29 erythema multiforme 9.9
30 sarcoma 9.9
31 ichthyosis 9.9
32 palmoplantar keratosis 9.9
33 acquired immunodeficiency syndrome 9.9
34 t-cell leukemia 9.9
35 kaposi sarcoma 9.8
36 systemic lupus erythematosus 9.8
37 mastocytosis, cutaneous 9.8
38 nevus anemicus 9.8
39 rheumatoid arthritis 9.8
40 pituitary adenoma 4, acth-secreting 9.8
41 hemochromatosis, type 1 9.8
42 leprosy 3 9.8
43 myasthenia gravis 9.8
44 mycosis fungoides 9.8
45 dermatitis, atopic 9.8
46 langerhans cell histiocytosis 9.8
47 aspergillosis 9.8
48 psoriasis 14, pustular 9.8
49 alopecia 9.8
50 arthritis 9.8

Comorbidity relations with Dermatophytosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Dermatophytosis:



Diseases related to Dermatophytosis
Sources

Symptoms & Phenotypes for Dermatophytosis

About this section

UMLS symptoms related to Dermatophytosis:


fever, pruritus, exanthema
Sources

Drugs & Therapeutics for Dermatophytosis

About this section

Drugs for Dermatophytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
2
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 29342-05-0 2749
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Amorolfine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 78613-35-1
5
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65277-42-1 3823 47576
6
Bifonazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60628-96-8 2378
7
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91161-71-6 1549008 5402
8
Efinaconazole Approved Phase 4,Phase 3,Not Applicable 164650-44-6
9
Naftifine Approved Phase 4,Phase 3,Phase 2,Phase 1 65472-88-0 47641 73342
10
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
11
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
12 Anti-Ulcer Agents Phase 4
13 Gastrointestinal Agents Phase 4,Phase 3
14 Antacids Phase 4
15 Proton Pump Inhibitors Phase 4
16 Keratolytic Agents Phase 4,Not Applicable
17 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Dermatologic Agents Phase 4,Phase 2,Not Applicable
22 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28
Hydroxyitraconazole Phase 4,Phase 3,Phase 2
29
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
30
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
31
Clotrimazole Approved, Vet_approved Phase 3,Phase 1 23593-75-1 2812
32
Econazole Approved Phase 3,Phase 2 27220-47-9 3198
33
Griseofulvin Approved, Investigational, Vet_approved Phase 3,Not Applicable 126-07-8 441140
34
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
35
Albendazole Approved, Vet_approved Phase 2, Phase 3 54965-21-8 2082
36 Papaya Approved Phase 2, Phase 3
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
39
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
40 Autonomic Agents Phase 3,Phase 2
41 Anti-Asthmatic Agents Phase 3,Phase 2
42 Respiratory System Agents Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 3,Phase 2
44 Cytochrome P-450 CYP2C19 Inhibitors Phase 3
45 Antiprotozoal Agents Phase 2, Phase 3,Not Applicable
46 Trace Elements Phase 2, Phase 3,Not Applicable
47 Antiparasitic Agents Phase 2, Phase 3,Not Applicable
48 Antimitotic Agents Phase 2, Phase 3
49 Micronutrients Phase 2, Phase 3,Not Applicable
50 Anthelmintics Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Unknown status NCT02394340 Phase 4 Omeprazole 40mg
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
4 An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
5 Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
6 Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
7 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
8 Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
9 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
10 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
11 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
12 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
13 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
14 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
15 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
16 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
17 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
18 Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
19 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Recruiting NCT03280927 Phase 4 Jublia®
20 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
21 Study Evaluating the Effect of Jublia on Dermatophytomas Active, not recruiting NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
22 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Active, not recruiting NCT03110029 Phase 4 Efinaconazole 10% (Jublia)
23 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Active, not recruiting NCT02812771 Phase 4 Efinaconazole
24 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
25 Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
26 Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Unknown status NCT01105013 Phase 3 Clotrimazole
27 Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Unknown status NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
28 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
29 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
30 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
31 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
32 Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
33 Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Completed NCT01349998 Phase 3 Product 33525
34 Topical Antifungal Treatment for Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
35 Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
36 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
37 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
38 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
39 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
40 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
41 Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
42 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
43 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris Completed NCT00750152 Phase 3 NAFT-500;Placebo
44 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
45 Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
46 A Study Of Diflucan In Children With Ringworm Of The Scalp Completed NCT00645242 Phase 3 fluconazole
47 BE Study of Naftifine HCL Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
48 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
49 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
50 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle

Search NIH Clinical Center for Dermatophytosis

Sources

Genetic Tests for Dermatophytosis

About this section
Sources

Anatomical Context for Dermatophytosis

About this section

MalaCards organs/tissues related to Dermatophytosis:

41
Skin, Testes, T Cells, Thymus, Liver, Lymph Node, Pituitary

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatophytosis:

19
Nail, Scalp, Glabrous Skin
Sources

Publications for Dermatophytosis

About this section

Articles related to Dermatophytosis:

(show top 50) (show all 993)
# Title Authors Year
1
Evaluation of the value of staining hair samples with a modified Wright-Giemsa stain and/or showing illustrated guidelines for the microscopic diagnosis of dermatophytosis in cats. ( 29664175 )
2018
2
Comparison of real-time PCR with fungal culture for the diagnosis of Microsporum canis dermatophytosis in shelter cats: a field study. ( 29172910 )
2018
3
Landscape of long non-coding RNAs in Trichophyton mentagrophytes-induced rabbit dermatophytosis lesional skin and normal skin. ( 29560532 )
2018
4
Assessment of a pan-dermatophyte nested-PCR compared with conventional methods for direct detection and identification of dermatophytosis agents in animals. ( 29944743 )
2018
5
Is Antifungal Resistance a Cause for Treatment Failure in Dermatophytosis: A Study Focused on Tinea Corporis and Cruris from a Tertiary Centre? ( 29644192 )
2018
6
Emergence of recalcitrant dermatophytosis in India. ( 29485088 )
2018
7
Indian irrational skin creams and steroid-modified dermatophytosis - an unholy nexus and alarming situation. ( 29706004 )
2018
8
Image Gallery: Molluscum contagiosum-like facial lesions in a patient with a renal transplant: deep dermatophytosis due to Trichophyton rubrum. ( 29785830 )
2018
9
Dermatophytosis in a psoriatic patient treated with secukinumab: an underrated adverse effect? ( 29767491 )
2018
10
Diffuse dermatophytosis occurring on dimethyl fumarate therapy. ( 29649923 )
2018
11
Reinterpreting minimum inhibitory concentration (MIC) data of itraconazole versus terbinafine for dermatophytosis - time to look beyond the MIC data? ( 29243676 )
2018
12
Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. ( 29094463 )
2018
13
Emergence of recalcitrant dermatophytosis in India. ( 29976522 )
2018
14
Erratum: Intracutaneous pharmacokinetics of oral antifungals and their relevance in recalcitrant cutaneous dermatophytosis: Time to revisit basics. ( 29657191 )
2018
15
Psoriasiform Dermatophytosis in a Bulgarian Child. ( 29484004 )
2018
16
IL-17-Mediated Immunity Controls SkinA Infection and T Helper 1 Response during Experimental Microsporum canisA Dermatophytosis. ( 29571944 )
2018
17
Tinea Capitis Masquerading as Basal Cell Carcinoma. ( 30207532 )
2018
18
Tiefe Trichophytie unter dem Bild einer Blepharitis - Tinea ciliaris. ( 29989360 )
2018
19
IL-17 Takes Center Stage in Dermatophytosis. ( 30032786 )
2018
20
Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). ( 30041646 )
2018
21
A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India. ( 30058568 )
2018
22
Erratum for Nagesh et al., phytochemical analysis and docking study of compounds present in a polyherbal preparation used in the treatment of dermatophytosis. ( 30186992 )
2018
23
A clarion call for preventing taxonomical errors of dermatophytes using the example of the novel Trichophyton mentagrophytes genotype VIII uniformly isolated in the Indian epidemic of superficial dermatophytosis. ( 30187579 )
2018
24
A Distinct Clinicopathological Presentation of Cutaneous Dermatophytosis Mimicking Autoimmune Blistering Disorder. ( 30210164 )
2018
25
Th1 and Th17 immune responses act complementarily to optimally control superficial dermatophytosis. ( 30227138 )
2018
26
In vivo antifungal activity of dipyrithione against Trichophyton rubrum on guinea pig dermatophytosis models. ( 30243089 )
2018
27
Diagnosis of dermatophytosis using single fungus endogenous fluorescence spectrometry. ( 30258686 )
2018
28
STAT3 and inherited susceptibility to invasive dermatophytosis. ( 30259966 )
2018
29
Dermatophytosis of the diaper area: Case report and literature review. ( 30284315 )
2018
30
'End of the road for terbinafine' in dermatophytosis: Is it a valid conclusion? ( 30289120 )
2018
31
Widespread Dermatophytosis in a Patient Treated for Leprosy Type II Reactional State after MDT/WHO-MB Release. ( 30292246 )
2018
32
Cover Image: Trichophyton rubrum penetration of horny cells in dermatophytosis. ( 30318795 )
2018
33
Burden of Chronic Dermatophytosis in a Tertiary Care Hospital: Interaction of Fungal Virulence and Host Immunity. ( 30386967 )
2018
34
Dermatophytosis: Prevalence of Dermatophytes and Non-Dermatophyte Fungi from Patients Attending Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia. ( 30402089 )
2018
35
A randomized, double-blind trial of amorolfine 0.25% cream and sertaconazole 2% cream in limited dermatophytosis. ( 30409926 )
2018
36
Disseminated dermatophytosis due to Nannizzia gypsea (Microsporum gypseum) in an elderly patient. ( 30467900 )
2018
37
Intralesional steroids in dermatophytosis: Quackery in India takes new route. ( 30504531 )
2018
38
Profile of Dermatophytosis in a Tertiary Care Center. ( 30504978 )
2018
39
Comparative effectiveness of Sumaq and Neem extract cream, Eniloconazole and glycerine iodine on dermatophytosis in Arabian horses: a randomized clinical trial. ( 30554365 )
2018
40
Kerion and tinea capitis. ( 29988774 )
2018
41
Three Skulls Dating from the French Revolutionary Years Diagnosed with Tinea Capitis: A Paleopathologic Approach. ( 30169450 )
2018
42
Reflectance confocal microscopy of tinea capitis: comparing images with results of dermoscopy and mycological exams. ( 30229878 )
2018
43
Morse code-like hairs in tinea capitis disappear after successful treatment. ( 30264392 )
2018
44
Scalp BCC's and meningioma following X-ray epilation for tinea capitis. ( 30378096 )
2018
45
Utility of trichoscopy in tinea capitis. ( 30425136 )
2018
46
Pediatric tinea capitis caused by Trichophyton violaceum and Trichophyton soudanense in Rochester, Minnesota, United States. ( 30548845 )
2018
47
Tinea Imbricata. ( 29747932 )
2018
48
Pustular tinea manuum from Trichophyton erinacei infection. ( 30023416 )
2018
49
Tinea corporis by Microsporum canis in mycological laboratory staff: Unexpected results of epidemiological investigation. ( 30030967 )
2018
50
A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis. ( 30124729 )
2018
Sources

Variations for Dermatophytosis

About this section
Sources

Expression for Dermatophytosis

About this section
Search GEO for disease gene expression data for Dermatophytosis.
Sources

Pathways for Dermatophytosis

About this section

Pathways related to Dermatophytosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
GPCRs, Class B Secretin-like 1
10 ADGRL1 ADGRL2
Sources

GO Terms for Dermatophytosis

About this section

Biological processes related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-negative bacterium GO:0050829 9.26 DEFB4A LTF
2 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.16 DEFB4A LTF
3 antimicrobial humoral response GO:0019730 8.96 DEFB4A LTF
4 killing of cells of other organism GO:0031640 8.62 DEFB4A LTF

Molecular functions related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 latrotoxin receptor activity GO:0016524 8.62 ADGRL1 ADGRL2
Sources

Sources for Dermatophytosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....